Matches in DBpedia 2014 for { <http://dbpedia.org/resource/LY-320,135> ?p ?o. }
Showing items 1 to 38 of
38
with 100 items per page.
- LY-320,135 abstract "LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s. LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses.".
- LY-320,135 casNumber "176977-56-3".
- LY-320,135 iupacName "4-[6-methoxy-2-(4-methoxyphenyl)1-benzofuran-3-carbonyl]benzonitrile".
- LY-320,135 pubchem "5311257".
- LY-320,135 thumbnail LY-320,135.png?width=300.
- LY-320,135 wikiPageID "17305129".
- LY-320,135 wikiPageRevisionID "525861108".
- LY-320,135 c "24".
- LY-320,135 casNumber "176977".
- LY-320,135 h "17".
- LY-320,135 hasPhotoCollection LY-320,135.
- LY-320,135 iupacName "4".
- LY-320,135 iupharLigand "742".
- LY-320,135 molecularWeight "383.395".
- LY-320,135 n "1".
- LY-320,135 o "4".
- LY-320,135 pubchem "5311257".
- LY-320,135 smiles "c3ccccc3-c2oc1ccccc1c2Cc4ccccc4".
- LY-320,135 verifiedrevid "424674882".
- LY-320,135 watchedfields "changed".
- LY-320,135 subject Category:Benzofurans.
- LY-320,135 subject Category:CB1_receptor_antagonists.
- LY-320,135 subject Category:Cannabinoids.
- LY-320,135 subject Category:Eli_Lilly_and_Company.
- LY-320,135 subject Category:Ketones.
- LY-320,135 subject Category:Nitriles.
- LY-320,135 subject Category:Phenol_ethers.
- LY-320,135 type Drug.
- LY-320,135 type DrugProduct.
- LY-320,135 type FunctionalSubstance.
- LY-320,135 comment "LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s. LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors.".
- LY-320,135 label "LY-320,135".
- LY-320,135 sameAs m.043kqry.
- LY-320,135 sameAs Q6460421.
- LY-320,135 sameAs Q6460421.
- LY-320,135 wasDerivedFrom LY-320,135?oldid=525861108.
- LY-320,135 depiction LY-320,135.png.
- LY-320,135 isPrimaryTopicOf LY-320,135.
